Table 1.
Demographic and clinical characteristics.
| HC (n = 68) | PD (n = 94) | p value | |
|---|---|---|---|
| Age | 60.75 ± 7.41 | 60.64 ± 8.69 | 0.931 |
| Gender (M/F) | 29/39 | 57/37 | 0.024* |
| Education | 8.24 ± 3.31 | 8.27 ± 4.38 | 0.952 |
| Disease duration | – | 3.92 ± 2.49 | – |
| Duration of drug administration | – | 2.94 ± 2.54 | – |
| LED | – | 435.00 ± 303.30 | – |
| UPDRS I | – | 1.34 ± 1.51 | – |
| UPDRS II | – | 6.82 ± 4.15 | – |
| UPDRS III | – | 17.23 ± 10.62 | – |
| H-Y | – | 2.05 ± 0.56 | – |
| MoCA | 24.86 ± 2.59 | 22.80 ± 5.21 | 0.001* |
| CNRLC | 1.97 ± 0.65 | 1.60 ± 0.44 | <0.001* |
HC: Healthy control; PD: Parkinson’s disease; LED: Levodopa equivalent daily dose; UPDRS: Unified Parkinson’s Disease Rating Scale; H-Y: Hoehn–Yahr; MoCA: Montreal Cognitive Assessment; CNRLC: Contrast-to-noise ratio of the locus coeruleus.
Mean value and standard deviation were shown. p < 0.05 is considered as significant, and marked as *.